Noile-Immune Biotech Inc.
|
Code |
Sector |
Market |
Lead Underwriter |
Date of listing approval |
IPO Date |
4893 |
Pharmaceuticals |
Growth |
SMBC Nikko |
2023/05/25 |
2023/06/28 |
【Description】 |
|
IPO Information |
Opening Price |
Y695 |
Total Amount |
Y3,083,136,000 |
IPO Price |
Y740 |
--Company |
Y2,466,538,400 |
Aggregate Value (based on Initial Price) |
30,026 (Unit:1 million) |
--Leading Shareholder |
Y369,946,720 |
Listed Shares(total) |
4,166,400 |
--Lead Manager |
Y246,650,880 |
Trading Unit |
100 |
|
Offering Price PER (based on previous period) |
-74.97 |
Offering Price PBR (based on previous period) |
6.82 |
公開価格PER(今期予想ベース) |
-16.72 |
Initial Price PER |
-70.42 |
Initial Price PBR |
6.41 |
New Shares |
3,623,000 |
Existing Shares |
543,400(only O.A.) |
Shares Outstanding |
Pre IPO |
39,579,865.00 |
PostIPO |
43,202,865.00 |
Paid Up Capital |
PreIPO |
Y2,787,552,000 |
PostIPO |
Y3,134,419,600 |
Use of Funds Raised |
|
Financial Data |
Units:Y1,000 |
Fiscal Year End |
|
Revenue |
Current Profit |
Net Profit |
Net Assets |
2020/12 |
Consolidated |
- |
- |
- |
- |
Non-consolidated |
97,277 |
-604,610 |
-636,649 |
2,598,379 |
2021/12 |
Consolidated |
- |
- |
- |
- |
Non-consolidated |
100,732 |
-792,615 |
-795,035 |
4,185,334 |
2022/12 |
Consolidated |
- |
- |
- |
- |
Non-consolidated |
625,783 |
-384,202 |
-386,622 |
4,300,617 |
Recent Quarter
2023/03 |
Consolidated |
- |
- |
- |
- |
Non-consolidated |
8,101 |
-493,787 |
-494,395 |
3,806,221 |
Results Forecast
2023/12 |
Consolidated |
- |
- |
- |
- |
Non-consolidated |
319,000 |
-1,832,000 |
-1,834,000 |
- |
Per Share |
Units:Y1 |
Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
2020/12 |
Consolidated |
0.00 |
- |
- |
|
Non-consolidated |
-17.93 |
72.24 |
|
2021/12 |
Consolidated |
0.00 |
- |
- |
|
Non-consolidated |
-20.75 |
107.30 |
|
2022/12 |
Consolidated |
0.00 |
- |
- |
|
Non-consolidated |
-9.87 |
108.48 |
|
Fiscal Year End |
|
Dividend |
Net Earning |
Equity |
|
Recent Quarter
2023/03 |
Consolidated |
|
- |
- |
|
Non-consolidated |
-12.49 |
- |
|
Results Forecast
2023/12
| Consolidated
| 0.00 |
- |
- |
|
Non-consolidated |
-44.27 |
- |
|
Comment |
■Over allotment(543,400) |
Consolidated Subsidiaries |
Name |
Address |
Underwriters |
Allocation |
Underwriter |
Tel |
80.1% |
SMBC Nikko |
03-5644-3111 |
8% |
SBI SECURITIES Co.,Ltd. |
03-5562-7210 |
4.2% |
Nomura |
03-3211-1811 |
4.2% |
Mizuho |
03-5208-3210 |
0.5% |
Toyo |
03-5117-1040 |
0.5% |
IwaiCosmo Securities Co.,Ltd. |
06-6229-2890 |
0.5% |
Akatsuki Securities |
03-5641-7800 |
0.5% |
Marusan |
03-3272-5211 |
0.5% |
Kyokuto |
03-3667-9171 |
0.5% |
Monex |
03-4323-3800 |
0.5% |
Okasan |
03-3272-2211 |
Data |
Date of incorporation |
2015/04/16 |
Company address |
Tokyo 105-0012 |
Telephone |
03-5843-7819 |
President |
|
Homepage |
https://www.noile-immune.com/ |
Auditor |
Tohmatsu |
|
|
Major Shareholders |
Shareholder Name |
Ratio |
|
23.27% |
|
19.14% |
|
9.88% |
|
5.73% |
|
5.37% |
|
4.71% |
|
4.71% |
|
3.21% |
|
3.18% |
|
2.84% |
Number of Employees |
22 as of 2023/04/30 |
Birth Date of Representative |
1968/03/28 |
|
|
IPO最新情報、セミナー・イベント情報などをタイムリーにお届けします。
|
|
IPO関連ニュースをX(旧Twitter)でも掲載中。初値予想アンケートも実施中です!
|
|
今後の躍進が期待される注目銘柄のアナリストレポートをご覧いただけます。
|
|
個人投資家向けIRセミナーを開催しませんか?開催希望企業募集中!
|
|